Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

NCT05299580 is registered in ClinicalTrials.gov with Fondazione Melanoma Onlus as lead sponsor.

NCT NCT05299580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05299580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
Lead sponsor
Fondazione Melanoma Onlus
Phase
Phase 2
Overall status
Withdrawn
Start date
February 18, 2021
Completion date
March 30, 2023
Enrollment
0 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma